MedPage Today on MSN6d
Twice-Yearly Biologic Effective Against Nasal Polyps
Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...
MedPage Today on MSN6d
Tezspire Treats Chronic Sinus Symptoms With Nasal Polyps
Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
China Daily2d
New medication shows promise in treating chronic sinusitis with nasal polyps
The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...
The New England Journal of Medicine7d
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...
Clinical Trials Arena6d
Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP
Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...
Twice-yearly drug eases symptoms in chronic rhinosinusitis with polyps
An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...
MedPage Today7d
Twice-Yearly Biologic Effective Against Nasal Polyps
Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections ...
MedPage Today7d
Tezspire Treats Chronic Sinus Symptoms With Nasal Polyps
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also ...